Previous 10 | Next 10 |
2024-03-25 12:30:02 ET UBS analyst issues UNDERPERFORM recommendation for GDRX on March 25, 2024 11:00AM ET. The previous analyst recommendation was Underperform. GDRX was trading at $7.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-03-25 12:30:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for GDRX on March 25, 2024 11:00AM ET. The previous analyst recommendation was Sector Perform. GDRX was trading at $7.41 at issue of the analyst recommendation. The overall analyst consensus ...
2024-03-21 11:33:43 ET Summary HIMS has been one of the best-performing growth stocks with a 465% return since its 2022 bottom and a 63% return year-to-date. The most successful growth stocks in history share five characteristics, which HIMS scores very good on. I provide a deep d...
2024-03-20 06:48:59 ET Summary GoodRx Holdings continues to perform strongly, reinforcing the view of a compelling product with a long growth runway. GDRX reported strong financials, with net revenue growth and better-than-expected margins. The early traction of the integrated...
2024-03-14 08:16:16 ET More on GoodRx Holdings GoodRx Holdings, Inc. (GDRX) Q4 2023 Earnings Call Transcript GoodRx: Cost Saving Is A Strong Value Proposition To Consumers GoodRx Stock Spikes After Receiving A Strong Dose Of Performance GoodRx stock climbs 6%...
Company Announces Board Resignations GoodRx Holdings, Inc. (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced Interim CEO Scott Wagner has extended his commitment to the Company. In addition, Stephen LeSieur and Adam Karol have notified GoodRx ...
2024-02-29 18:38:22 ET Shares of GoodRx Holdings (NASDAQ: GDRX) rallied by 20.4% on Thursday after the company announced stronger-than-expected quarterly results and a new stock buyback program. In the fourth quarter, GoodRx's revenue grew 7% year over year to $196.6 million, tr...
2024-02-29 13:15:18 ET Image source: The Motley Fool. GoodRx (NASDAQ: GDRX) Q4 2023 Earnings Call Feb 29, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: GoodRx (GDRX) Q4 2023 Earnings Call Transcript
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on ...
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...
News, Short Squeeze, Breakout and More Instantly...
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® PR Newswire First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and S...
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management ...
Former Genentech CEO brings over 35 years of pharmaceutical and healthcare expertise to GoodRx GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced the ...